Skip to content

Dr. Lassandro Nicola Vito

Ophthalmologist, Researcher
Lassandro (1)
Research line: Research Line of Medical and surgical retina
Research unit: RU Medical Retina
Simple Operating Unit: Simple Operating Unit Medical Retina, low vision and visual rehabilitation 
Specialization: Ophthalmology
Professional register: Registered with the Provincial Register of Surgeons and Physicians of Rome (Order of the Province of Rome), Registration No. 61833, dated July 29, 2015.

Practices at IRCCS Fondazione G.B. Bietti, in the facilities of Via Livenza, 3 and Via di Santo Stefano Rotondo, 6, at the Presidio Ospedaliero Britannico, Rome.

Scientific Publications: Pubmed

  • 11/01/2015–11/18/2019: Specialization Diploma in Ophthalmology (Residency) at the Marche Polytechnic University (Università Politecnica delle Marche), graduating with full marks (50/50) and honors (cum laude). Experimental Thesis titled: “Pachychoroid Pigment Epitheliopathy and Analysis of Choroidal Blood Flow in Patients with Cushing’s Disease: a Study with Optical Coherence Tomography Angiography.” Supervisor: Prof. Cesare Mariotti.
  • 09/01/2015: Qualification/License for the professional practice of Surgeon and Physician (270/270) at the Catholic University of the Sacred Heart.
  • 10/2008–03/11/2015: Master’s Degree in Medicine and Surgery (MD) at the Catholic University of the Sacred Heart. Experimental Thesis titled: “Dopamine Transporter (DAT) Availability in Pathological Gambling: an Experimental Study using the 123 I -FP-CIT SPECT Technique.” Supervisor: Prof. Gianluigi Conte. Co-Supervisor: Prof. Daniela Di Giuda.
  • May 2024–Present: Physician Researcher in the Medical Retina service at IRCCS Fondazione G.B. Bietti.
  • 10/01/2020–04/15/2024: Staff Ophthalmologist (Dirigente Medico di Oftalmologia) at the University Hospital “Ospedali Riuniti Umberto I – G.M. Lancisi – G. Salesi.”
  • 03/01/2020–09/30/2020: University Research Fellowship (Assegno di ricerca) at the Marche Polytechnic University (Università Politecnica delle Marche). Research title: “The Impact of OCT Technology in the Management of Diabetic Retinopathy,” carried out at the Department of Experimental and Clinical Medicine and the U.O.C. of Ophthalmology.
  • 11/26/2019–09/30/2020: Outpatient Specialist in Ophthalmology (Specialista Ambulatoriale) at ASUR Marche.
  • 03/25/2019–06/30/2019: Ophthalmology Resident (Medico Specializzando) at the Ecclesiastical Entity Regional General Hospital “Francesco Miulli.”
  • Italian Association of Ophthalmic Physicians (AIMO)
  • S.I.S.O. ETS (Italian Society of Ophthalmological Sciences Third Sector Entity)
  • Study investigator Studio CENTERABAY86–5321/17514: multicenter single arm, interventional Phase 4 study to evaluate a treat and extend regimen of intravitreal aflibercept treatment for macular edema secondary to central vein occlusion.
  • Study investigator Studio ARRAY- 818-302: The BEACON CRC Study: This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator’s choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.
  • Study investigator Studio IVERIC BIO ISEE2008: Studio clinico di fase III multicentrico, randomizzato, in doppio cieco, controllato con trattamento simulato, volto a valutare la sicurezza e l’efficacia della somministrazione intravitreale di Zimura™ (inibitore del componente C5 del complemento) in pazienti con atrofia geografica secondaria a degenerazione maculare senile.
  • Study investigator OPTH Studio SGN22E-003: An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
  • Study investigator Studio CRTH258AIT04 IMAGINE: One year, single arm, open label,multicenter,phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with Brolucizumab.
  • Study investigator Studio IVERIC BIO ISEE2009: An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2).
  • Study investigator Study QUASAR: PROTOCOL BAY 86-5321 : Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) .

 

 

Skip to content